Publications
Chosen filters:
Chosen filters:
The spectrum of Lewy Body brain disorders University of Antwerp
Activation of ErbB4 attenuates atrial fibrillation in mice University of Antwerp
Atrial fibrillation (AF), the most common arrhythmia, results from electrical and structural remodeling of the atria. Current therapies focus on symptomatic treatment and do not target the structural problem. This implies a high medical need for new AF therapies. The neuregulin-1 (NRG1)/ERBB system plays a compensatory role during heart failure by acting on cardiomyocytes and mitigates fibrosis in different tissues, including the myocardium. In ...
Application of solid lipid nanoparticles as a drug delivery platform for parenteral and oral administration University of Antwerp
The development of new drug molecules is an important element of the extended lifespan and improved human health around the globe. Many new drug candidates are highly lipophilic causing solubility and formulation stability issues. This poses a challenge for formulation scientists to develop an optimal drug delivery system for oral and parenteral administration of these drugs. Solid lipid nanoparticles (SLNs) have attracted increasing attention ...
Unravelling disease signatures in Charcot-Marie-Tooth disease using induced pluripotent stem cells University of Antwerp
Charcot-Marie-Tooth (CMT) disease is an inherited peripheral neuropathy caused by mutations in various genes. It is a genetically diverse group of disorders with over 1000 mutations in more than 90 genes associated with the disease. CMT affects approximately 1 in 2500 individuals worldwide and is categorized into demyelinating (CMT1) and axonal (CMT2) forms based on the primary deficits occurring in Schwann cells or neuronal axons. Despite its ...
Characterization of occurrence, metabolism and contribution to human exposure of new plasticizers present in the indoor environment University of Antwerp
Recently, several changes have been made to the chemical composition of products used indoors. Legacy chemicals have been replaced by “alternatives” due to evidence for adverse health effects of the former. However, there is still limited information related to the human exposure to these replacement chemicals. Therefore, there is urgent need to investigate their occurrence indoors and the extent of the human exposure to them. In this regard, ...
An integrated strategy to characterize new anti-inflammatory lead compounds derived from **Filipendula ulmaria** (meadowsweet) University of Antwerp
The scope of this PhD thesis was to develop an integrated strategy, based on natural pro-drugs and their metabolites, to characterize new anti-inflammatory lead compounds derived from Filipendula ulmaria. The plant is widely used in phytotherapy against inflammatory diseases. However, its active constituents are not exactly known. It contains many constituents, such as flavonoid glycosides, which are not absorbed. However, these compounds are ...
Development of a PLGA-based nanoparticle drug delivery system for the targeting of macrophages University of Antwerp
Macrophages are involved in many biological processes and are therefore, unfortunetaly, involved in several conditions. That’s why they may serve as therapeutic targets during infection, cancer or inflammatory diseases, but can also be addressed for antigen presentation. Due to their phagocytic nature, macrophages are attractive candidates for particle-based drug delivery systems. Nanoparticles gained a lot of interest lately as drug delivery ...
Biofilm-related pneumonia University of Antwerp
Biofilm-related infections are a major threat to healthcare as they underlie treatment failure. The main question we pose is: Can we improve strategies to prevent biofilm-related lung infections? To prevent such infections, we must first understand how biofilms contribute to their chronic nature. The in vitro biofilm differs from the in vivo biofilm and we aimed at evaluating both. For in vitro evaluation, an interlaboratory effort was made to ...
The identification of small-molecule ERBB4 agonists University of Antwerp
ERBB4 is a member of the epidermal growth factor subfamily of receptor tyrosine kinase receptors and regulates signaling pathways involved in cardiac development, biology and disease. The endogenous ligand NRG1 is of particular importance in the heart, signaling through the ERBB4 and ERBB2 receptor. Activation of ERBB4 by NRG1 plays well-defined roles in heart failure and elicits antifibrotic effects in the heart by attenuating cell death, ...